Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study (Q38459890)

3 September 2017

Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study (English)

1 reference

3 September 2017

1 reference

1 reference

Jeffrey M Hardacre

1

1 reference

3 September 2017

Mary Mulcahy

2

1 reference

3 September 2017

William Small

3

1 reference

3 September 2017

Mark Talamonti

4

1 reference

3 September 2017

Jennifer Obel

5

1 reference

3 September 2017

Smitha Krishnamurthi

6

1 reference

3 September 2017

Caio S Rocha-Lima

7

1 reference

3 September 2017

Howard Safran

8

1 reference

3 September 2017

Heinz-Joseph Lenz

9

1 reference

3 September 2017

E Gabriela Chiorean

10

1 reference

3 September 2017

15 November 2012

1 reference

Journal of Gastrointestinal Surgery

3 September 2017

1 reference

3 September 2017

17

1 reference

3 September 2017

1

1 reference

3 September 2017

94-100; discussion p. 100-1

1 reference

https://scigraph.springernature.com/pub.10.1007/s11605-012-2064-6

3 September 2017

0 references

cites work

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Xenotransplantation: the importance of the Galalpha1,3Gal epitope in hyperacute vascular rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Lack of galactose-alpha-1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

The anticancer immune response: indispensable for therapeutic success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11605-012-2064-6

Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer

21 January 2018

1 reference

12 December 2020

Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora

1 reference

12 December 2020

Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells

1 reference

12 December 2020

Removal of terminal alpha-galactosyl residues from xenogeneic porcine endothelial cells. Decrease in complement-mediated cytotoxicity but persistence of IgG1-mediated antibody-dependent cell-mediated cytotoxicity

1 reference

12 December 2020

Antibody-dependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera

1 reference

12 December 2020

10.1007/S11605-012-2064-6

Identifiers

DOI

1 reference

3 September 2017

1 reference